U.S. markets open in 4 hours 56 minutes

Albireo Pharma, Inc. (ALBO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
19.18+0.64 (+3.45%)
At close: 04:00PM EDT
19.18 0.00 (0.00%)
After hours: 04:08PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close18.54
Bid0.00 x 1400
Ask0.00 x 1000
Day's Range18.31 - 19.53
52 Week Range17.81 - 37.86
Avg. Volume296,064
Market Cap375.473M
Beta (5Y Monthly)0.98
PE Ratio (TTM)N/A
EPS (TTM)-1.70
Earnings DateAug 03, 2022 - Aug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est70.40
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ALBO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Albireo Pharma, Inc.
    Daily – Vickers Top Buyers & Sellers for 06/29/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • Simply Wall St.

    Albireo Pharma, Inc. (NASDAQ:ALBO): When Will It Breakeven?

    We feel now is a pretty good time to analyse Albireo Pharma, Inc.'s ( NASDAQ:ALBO ) business as it appears the company...

  • GlobeNewswire

    Albireo Presents New Bylvay® (odevixibat) Data at Annual ESPGHAN Congress

    Four presentations highlight newest data from landmark Phase 3 PEDFIC 1 and PEDFIC 2 trials, largest studies completed in PFICNew analysis show potential for greater response and higher proportion of pruritus responders with dose escalation and consistent tolerability across dosesLong-term data provide evidence of consistent improvements in hepatic parameters, growth, sleep, and biomarkers in patients with all PFIC types with treatment up to 72 weeks BOSTON, June 24, 2022 (GLOBE NEWSWIRE) -- Alb

  • GlobeNewswire

    Albireo Announces Presentation of New Data in Pediatric and Adult Liver Diseases

    New analyses of PEDFIC Phase 3 trials show that patients whose pruritus improves on Bylvay® (odevixibat) also experience improvements in sleep, quality of life, serum bile acids and hepatic parametersLong-term data from PEDFIC trials of Bylvay show dramatic quality of life deficits in patients and families affected by PFICStudies show consistent and sustained efficacy for Bylvay across all PFIC types Announces new SPARK Grants Program, accepting applications for projects to improve care for rare